Log In
Print this Print this

Malaria vaccine

  Manage Alerts
Collapse Summary General Information
Company iBio Inc.
DescriptionMalaria vaccine based on a portion of the Pfs230 antigen from Plasmodium falciparum developed using iBioLaunch technology
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationMalaria
Indication DetailsVaccinate against malaria
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today